Odyssey Therapeutics, Inc. ($ODTX)
Filing Information
| Accession Number | 0001193125-26-217607 |
|---|---|
| Form Type | 4 |
| Filing Date | May 12, 2026 |
| Document | View SEC Filing |
Transactions
9
Total Shares
966,866
Total Value
$100,306.00
P&L
+11224.1% (+$11,224,086.80)
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Director | Common Stock | โ | May 8, 2026 | Purchase | 5,000 | $20.00 | $100,000.00 | 270,198 | Direct | โ | View Details | |
Director | Common Stock | โ | May 11, 2026 | Conversion | 28,698 | โ | โ | 28,698 | Indirect | See footnote | View Details | |
Director | Common Stock | โ | May 11, 2026 | Exercise/Conversion | 2,963 | โ | โ | 31,661 | Indirect | See footnote | View Details | |
Director | Common Stock | โ | May 11, 2026 | Tax Withholding | 17 | $18.00 | $306.00 | 31,644 | Indirect | See footnote | View Details | |
Director | Series B Convertible Preferred Stock | Derivative | May 11, 2026 | Conversion | 79,166 | โ | โ | 0 | Indirect | See footnote | View Details | |
Director | Series C Convertible Preferred Stock | Derivative | May 11, 2026 | Conversion | 100,000 | โ | โ | 0 | Indirect | See footnote | View Details | |
Director | Series D Convertible Preferred Stock | Derivative | May 11, 2026 | Conversion | 96,002 | โ | โ | 0 | Indirect | See footnote | View Details | |
Director | Stock Option (Right to Buy) | Derivative | May 7, 2026 | Grant/Award | 626,220 | $0.00 | $0.00 | 626,220 | Direct | โ | View Details | |
Director | Series D Warrants (Right to Buy) | Derivative | May 11, 2026 | Exercise/Conversion | 28,800 | โ | โ | 0 | Indirect | See footnote | View Details |